ACIU

AC Immune Ltd (Ticker: ACIU) is an innovative clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in transformative therapies and diagnostics for neurodegenerative conditions associated with protein misfolding, particularly Alzheimer's disease. Utilizing its proprietary technology platforms, the company is dedicated to advancing a diverse pipeline of drug candidates designed to modify disease progression and improve patient outcomes. With a strategic focus on addressing critical unmet needs in neurology, AC Immune presents a compelling investment opportunity for institutional investors seeking to capitalize on breakthroughs in the biopharmaceutical landscape.